Close Menu

News / Events

EGeen International Selected As Full Service CRO for Cyxone Rabeximod Phase IIb Clinical Trial

EGeen International has been awarded a full services CRO contract by Cyxone of Sweden to conduct its’ upcoming clinical Phase IIb trial for the RA drug candidate Rabeximod. The multi-center Phase IIb trial is expected to begin patient recruitment in the first half of 2020. Cyxone, a Swedish biotech firm focusing on autoimmune diseases, recently submitted an application to the Central Ethics Committee (CEC) in Poland for permission to begin the clinical Phase IIb trial with Rabeximod.

Read More >

July 20, 2019

J.P. Morgan 37th Annual Healthcare Conference

EGeen representatives will be meeting future and present clients during the J.P. Morgan Conference in San Francisco on January 7-9, 2019.

Read More >

January 7-9, 2019

EGeen International Clinical Trial Services Result in Akorn ANDA Approval

MOUNTAIN VIEW, CA. – Following a successful clinical trial executed by EGeen International, Inc., its’ client, Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, recently received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration for diclofenac sodium topical gel, 1%.

Diclofenac sodium topical gel, 1% is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knee and hand joints. Diclofenac sodium topical gel, 1% has not been evaluated for use on the spine, hip, or shoulder.

EGeen’s trial result was notable as one of the first clinical trial successes in bringing a generic diclofenac product to the market using the WOMAC pain scale clinical endpoint study. The trial was completed under timeline and within the project budget.

EGeen International, Inc. is known for its’ Generic Drug Development (GDD) Program, leveraging the cost effective European trial environment to support worldwide filings and approvals of generic pharmaceutical products.

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.

Read More >

November 28, 2018

J.P. Morgan 36th Annual Healthcare Conference

EGeen representatives will be meeting future and present clients during the J.P. Morgan Conference in San Francisco on January 8-11, 2018.

Read More >

January 8-11, 2018

Laguna Biotech CEO Forum - Laguna Beach, CA

The CEO of EGeen International, Inc. , Dr. Kalev Kask, will be attending the upcoming Laguna Biotech CEO Forum in Laguna Beach, CA. Dr. Kask will be among leading biopharma CEOs as they discuss the current state and future direction of the biopharmaceutical industry.

Read More >

October 8-10, 2017

BIO 2017 Conference - San Diego, CA

EGeen International, Inc. attended and exhibited at the annual BIO conference held this year in San Diego, CA. EGeen management and representatives presented their latest clinical trial program updates and met industry colleagues in Booth No. 5648.

Read More >

June 17-22, 2017

DIA 2016 Conference – Philadelphia, PA

EGeen, Inc. will be attending and exhibiting at the upcoming DIA Conference on June 26-29, 2016. EGeen representatives will be discussing the company’s newest clinical trial programs at Booth No. 2440.

Read More >

June 26-29, 2016

DCAT week - New York City

EGeen representatives will be meeting future and present clients during the DCAT week in New York City on March 15 -17, 2016.

Read More >

March 1, 2016

Akorn Inc. Study Enrollment

EGeen has completed patient enrolment on time for Akorn, Inc.'s large clinical bioequivalance study.

Read More >

February 7, 2016